# Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR

> **NCT06763744** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 3000 (estimated)

## Conditions studied

- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- High Bleeding Risk

## Interventions

- **DRUG:** P2Y12 antagonist monotherapy
- **DRUG:** clopidogrel + aspirin

## Key facts

- **NCT ID:** NCT06763744
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2029-07-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06763744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06763744, "Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06763744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*